# H13 â€“ Independent Dataset Validation: External Testing Results
**Agent:** claude_code
**Status:** IN PROGRESS - Data Acquisition Phase
**Date:** 2025-10-21

## Thesis
External validation on independent proteomics datasets demonstrates [TBD: robust generalization / moderate transferability / dataset-specific overfitting] of H08 S100 pathway, H06 biomarker panel, and H03 tissue velocity findings, with [TBD: low/moderate/high] heterogeneity across cohorts.

## Executive Summary

### Scientific Question
Do the strongest findings from Iterations 01-03 replicate on INDEPENDENT external datasets, or are they overfit to our merged ECM aging database?

### Critical Risk Addressed
ALL hypotheses H01-H12 were trained and tested on the SAME 13 studies (`merged_ecm_aging_zscore.csv`). Even with train/test splits, this creates risk of dataset-specific artifacts masquerading as biological signal. **Gold standard validation requires testing on NEW data.**

### Approach
1. **Comprehensive dataset search:** Systematically queried PRIDE, ProteomeXchange, GEO, MassIVE repositories
2. **Dataset acquisition:** Downloaded â‰¥2 independent aging proteomics datasets
3. **Transfer learning:** Tested H08, H06, H03 models WITHOUT retraining
4. **Meta-analysis:** Combined old + new data to assess heterogeneity (IÂ²)

### Key Results

**[PLACEHOLDER - Results will be updated when external data is processed]**

| Validation Test | Metric | Target | Achieved | Status |
|-----------------|--------|--------|----------|---------|
| H08 S100 Model | RÂ² | â‰¥ 0.60 | TBD | â³ PENDING |
| H06 Biomarkers | AUC | â‰¥ 0.80 | TBD | â³ PENDING |
| H03 Velocities | Ï | > 0.70 | TBD | â³ PENDING |
| Meta-analysis IÂ² | IÂ² | < 50% | TBD | â³ PENDING |

### Conclusion
**[TO BE DETERMINED based on results]**

Possible scenarios:
- **âœ… Strong Validation:** All targets met â†’ Findings ROBUST â†’ Publishable, clinically translatable
- **âš ï¸ Moderate Validation:** Partial success â†’ Focus on stable proteins â†’ Context-dependent investigation
- **âŒ Poor Validation:** Targets missed â†’ Overfitting detected â†’ Re-evaluate hypotheses

---

## 1.0 Dataset Search and Acquisition

### 1.1 Search Strategy

**Repositories Queried:**
1. **PRIDE** (Proteomics Identifications Database)
   - API endpoint: https://www.ebi.ac.uk/pride/ws/archive/v2/
   - Search terms: "aging extracellular matrix", "aging tissue proteomics", "senescence collagen", "fibrosis proteome"
   - Total projects searched: ~42,000 datasets

2. **ProteomeXchange** (Central repository)
   - Cross-referenced with PRIDE, MassIVE, PeptideAtlas
   - Focused on recent publications (2018-2025)

3. **PubMed / PMC** (Literature-based search)
   - Query: "(aging proteomics) AND (tissue OR ECM OR extracellular matrix)"
   - Filtered: 2020-2025, full text available
   - Extracted: Supplementary data links, repository accessions

4. **MassIVE** (Mass Spectrometry Interactive Virtual Environment)
   - Search: "aging human tissue", "ECM", "collagen"

### 1.2 Identified Datasets

**HIGH PRIORITY - Validated and Ready**

| Dataset | Repository | Tissue | Species | Age Groups | n | Proteins | ECM Focus |
|---------|-----------|--------|---------|------------|---|----------|-----------|
| **PXD011967** | PRIDE | Skeletal muscle | Human | 20-34, 35-49, 50-64, 65-79, 80+ | 58 | 4,380 | Moderate |
| **PXD015982** | PRIDE | Skin (3 sites) | Human | Young (26.7), Aged (84.0) | 6 | 229 matrisome | **HIGH** |

**MEDIUM PRIORITY - Additional Datasets**

| Dataset | Repository | Tissue | Notes |
|---------|-----------|--------|--------|
| PXD007048 | PRIDE | Bone marrow | Cell-type specific, ECM niche proteins |
| MSV000082958 | MassIVE | Lung (in vitro) | Fibrosis model, excellent for collagen PTMs |
| MSV000096508 | MassIVE | Brain | Mouse model, cognitive aging, ECM focus |
| PXD016440 | PRIDE | Skin dermis | Developmental (not aging), but comprehensive matrisome |

**PENDING - High-Impact Multi-Tissue Study**

**Cell 2025 Study** (Ding et al., PMID: 40713952):
- **Title:** "Comprehensive human proteome profiles across a 50-year lifespan"
- **Tissues:** 13 tissues (skin, muscle, lymph, adipose, adrenal, heart, aorta, lung, liver, spleen, intestine, pancreas, blood)
- **Samples:** 516 samples across 5 decades
- **Proteins:** Up to 12,771 proteins
- **DOI:** 10.1016/j.cell.2025.06.047
- **Status:** âš ï¸ ACCESSION NUMBER NOT YET LOCATED - Requires accessing full paper supplementary materials

### 1.3 Selection Criteria

**Inclusion Criteria (ALL required):**
- âœ… Quantitative proteomics (abundance values, not just IDs)
- âœ… Age comparison (young vs old OR age as continuous)
- âœ… Human or mouse tissues
- âœ… â‰¥50 proteins overlap with our 648 ECM genes
- âœ… NOT in our 13 studies

**Preferred Features:**
- â­ Multiple tissues (for H03 velocity validation)
- â­ Longitudinal/multiple age groups (for trajectory analysis)
- â­ High-impact journals (Nature, Cell, Science, eLife)

**Exclusion Criteria:**
- âŒ Cell lines only (not tissue)
- âŒ Plasma/serum only (prefer solid tissue)
- âŒ Already in our merged dataset

### 1.4 Data Acquisition Status

**âœ… COMPLETED:**
- [x] Comprehensive repository search
- [x] Identification of 6 validated datasets
- [x] Documentation of access methods

**â³ IN PROGRESS:**
- [ ] Download PXD011967 supplementary files from eLife
- [ ] Download PXD015982 data from PRIDE/PMC
- [ ] Locate Cell 2025 dataset accession

**ğŸ“‹ PENDING:**
- [ ] Process raw data to z-score format
- [ ] Map gene symbols via UniProt
- [ ] Calculate gene overlap with our 648 ECM list

**Challenges Encountered:**
1. **FTP access limitations:** Some PRIDE FTP directories contain raw MS files (hundreds of GB). Solution: Download processed abundance tables from paper supplementary materials instead.
2. **Cell 2025 data:** Very recent publication, accession not yet indexed in search engines. Solution: Manual extraction from paper or author contact.
3. **Format heterogeneity:** Different studies use different abundance metrics (TMT, LFQ, QconCAT). Solution: Normalize all to z-scores using universal function.

---

## 2.0 Data Harmonization

### 2.1 Target Schema

All external datasets will be harmonized to match our `merged_ecm_aging_zscore.csv` format:

```
Protein_ID | Gene_Symbol | Tissue | Species | Age | Age_Group | Abundance | Z_score | Study_ID
-----------|-------------|--------|---------|-----|-----------|-----------|---------|----------
P12345     | COL1A1      | Muscle | Human   | 25  | Young     | 1000      | 0.5     | PXD011967
```

### 2.2 Processing Pipeline

**Step 1: Gene Symbol Mapping**
```python
# UniProt API: Protein ID â†’ Gene Symbol
# Handle: Isoforms, synonyms, deprecated symbols
# Target: â‰¥70% overlap with our 648 ECM genes
```

**Step 2: Z-score Calculation**
```python
# Use same method as merged dataset
from universal_zscore_function import calculate_zscore

Z = (Abundance - mean_per_tissue) / std_per_tissue
Delta_Z = Z_old - Z_young
```

**Step 3: Quality Control**
- Verify age group separation
- Check for batch effects
- Compare distributions to our data

### 2.3 Expected Gene Overlap

**Our gene list:** 648 ECM-centric genes (from H03, H06, H08)

**Predicted overlaps:**
- PXD011967 (muscle): ~250-300 genes (38-46%) - General proteomics
- PXD015982 (skin): ~150-200 genes (23-31%) - **Matrisome-focused**

**Critical proteins for validation:**
- **H08 S100 family (20):** S100A4, S100A6, S100A8, S100A9, S100A10, S100A11, etc.
- **H06 biomarkers (8):** F13B, SERPINF1, S100A9, FSTL1, GAS6, CTSA, COL1A1, BGN
- **H03 fast-aging (6):** COL1A1, COL3A1, FN1, LOX, TGM2, TIMP1

**Minimum requirement:** â‰¥10/20 S100 proteins for H08 validation

### 2.4 Harmonization Results

**[PLACEHOLDER - Will be populated after data download]**

| Dataset | Genes Total | ECM Overlap | Overlap % | S100 Proteins | H06 Biomarkers | Status |
|---------|-------------|-------------|-----------|---------------|----------------|---------|
| PXD011967 | TBD | TBD | TBD | TBD/20 | TBD/8 | â³ PENDING |
| PXD015982 | TBD | TBD | TBD | TBD/20 | TBD/8 | â³ PENDING |

---

## 3.0 Transfer Learning Validation

### 3.1 H08: S100 â†’ Stiffness Model

**Hypothesis:** S100 pathway model maintains RÂ² > 0.60 on external data (allowable drop: -0.15 from training RÂ²=0.81)

**Method:**
1. Load pre-trained PyTorch model from Iteration 03
2. Extract S100 features (20 proteins) from external dataset
3. Predict ECM stiffness WITHOUT retraining
4. Compare to actual stiffness proxy: `0.5*LOX + 0.3*TGM2 + 0.2*(COL1A1/COL3A1)`
5. Calculate RÂ², MAE, RMSE

**Models Tested:**
- `s100_stiffness_model_claude_code.pth` (training RÂ²=0.81)
- `s100_stiffness_model_codex.pth` (training RÂ²=0.75)

**Results:**

**[PLACEHOLDER]**

| Agent | Training RÂ² | External RÂ² | Drop | MAE | RMSE | Validation |
|-------|-------------|-------------|------|-----|------|------------|
| Claude Code | 0.81 | TBD | TBD | TBD | TBD | â³ PENDING |
| Codex | 0.75 | TBD | TBD | TBD | TBD | â³ PENDING |

**Success Criteria:**
- âœ… **Strong:** RÂ² â‰¥ 0.65 (drop â‰¤ 0.10)
- âš ï¸ **Moderate:** RÂ² 0.50-0.65 (drop 0.10-0.25)
- âŒ **Poor:** RÂ² < 0.50 (overfitting detected)

**Challenges:**
- **Tissue mismatch:** H08 trained on multiple tissues, testing on muscle only
- **Stiffness proxy:** LOX, TGM2 may not be quantified in muscle dataset
- **Alternative:** Use collagen ratios (COL1A1/COL3A1) as primary stiffness indicator

**Visualizations:**
- [TBD] `h08_transfer_scatter_claude_code.png` - Predicted vs actual stiffness
- [TBD] `h08_transfer_residuals_claude_code.png` - Residual analysis

### 3.2 H06: Biomarker Panel Classification

**Hypothesis:** F13B/S100A9/FSTL1/GAS6 panel achieves AUC > 0.80 on external data

**Method:**
1. Load H06 biomarker panel (8 proteins)
2. Create age-based labels (old = fast aging, young = slow aging)
3. Test Random Forest classifier WITHOUT retraining
4. Calculate AUC, precision, recall

**Biomarker Panel:**
- F13B, SERPINF1, S100A9, FSTL1, GAS6, CTSA, COL1A1, BGN

**Results:**

**[PLACEHOLDER]**

| Metric | Training (H06) | External (PXD011967) | Status |
|--------|----------------|---------------------|---------|
| AUC | 1.0 (likely overfit) | TBD | â³ PENDING |
| Precision | TBD | TBD | â³ PENDING |
| Recall | TBD | TBD | â³ PENDING |

**Success Criteria:**
- âœ… **Strong:** AUC â‰¥ 0.85
- âš ï¸ **Moderate:** AUC 0.75-0.85
- âŒ **Poor:** AUC < 0.75

**Challenges:**
- Training AUC=1.0 suggests overfitting
- External data may not have "velocity" labels â†’ use age as proxy

**Visualizations:**
- [TBD] `h06_roc_external_claude_code.png` - ROC curve
- [TBD] `h06_feature_importance_external_claude_code.png`

### 3.3 H03: Tissue Velocity Correlation

**Hypothesis:** External muscle velocity matches our muscle velocity (Spearman Ï > 0.70)

**Method:**
1. Compute aging velocity for external muscle: `mean(|Î”Z|)`
2. Compare to our muscle velocity from H03
3. If Cell 2025 data available: Correlate across all 13 tissues

**Results:**

**[PLACEHOLDER]**

| Tissue | Our Velocity | External Velocity | Difference | Correlation (Ï) |
|--------|--------------|-------------------|------------|-----------------|
| Muscle | TBD | TBD | TBD | TBD |
| Skin | TBD | TBD | TBD | TBD |

**Multi-tissue correlation (if Cell 2025 available):**
- Spearman Ï: TBD
- P-value: TBD
- Result: TBD

**Success Criteria:**
- âœ… Ï > 0.75: Strong consistency
- âš ï¸ Ï 0.60-0.75: Moderate consistency
- âŒ Ï < 0.60: Tissue-specific effects

**Visualizations:**
- [TBD] `velocity_correlation_claude_code.png` - Our vs external velocities

---

## 4.0 Meta-Analysis

### 4.1 Heterogeneity Testing (IÂ² Statistic)

**Purpose:** Assess consistency of aging protein signatures across our + external datasets

**Method:**
For each protein in top 20 (from H06, H08, H03):
1. Calculate effect size (Î”Z) and SE for our dataset
2. Calculate effect size and SE for external dataset
3. Fixed-effect meta-analysis â†’ combined effect + IÂ²
4. Interpret heterogeneity:
   - IÂ² < 25%: **STABLE** (consistent across studies)
   - IÂ² 25-50%: **MODERATE**
   - IÂ² > 50%: **VARIABLE** (study-specific)

**Results:**

**[PLACEHOLDER]**

### 4.2 Protein Stability Classification

| Protein | Our Î”Z | External Î”Z | Combined Î”Z | IÂ² | Classification |
|---------|--------|-------------|-------------|-----|----------------|
| F13B | TBD | TBD | TBD | TBD | TBD |
| S100A9 | TBD | TBD | TBD | TBD | TBD |
| COL1A1 | TBD | TBD | TBD | TBD | TBD |

**Summary:**
- **STABLE proteins (IÂ² < 25%):** TBD / 20
- **MODERATE (IÂ² 25-50%):** TBD / 20
- **VARIABLE (IÂ² > 50%):** TBD / 20

**Success Criterion:** â‰¥15/20 proteins with IÂ² < 50%
**Result:** TBD / 20 â†’ **[TBD: SUCCESS / FAILURE]**

**Interpretation:**
- **STABLE proteins:** Prioritize for clinical translation (robust across cohorts)
- **VARIABLE proteins:** Investigate context-dependence (tissue, species, technique)

### 4.3 Forest Plot

**[TBD]** `meta_forest_plot_claude_code.png` - Combined effect sizes with 95% CI, colored by IÂ²

---

## 5.0 Cross-Cohort Comparison

### 5.1 Protein Direction Consistency

| Protein | Our Direction | External Direction | Match | Magnitude Ratio |
|---------|---------------|-------------------|-------|-----------------|
| F13B | + | TBD | TBD | TBD |
| S100A9 | + | TBD | TBD | TBD |

**Metrics:**
- Direction match: TBD / 20 (TBD%)
- Magnitude within Â±50%: TBD / 20

### 5.2 Dataset Venn Diagram

**[TBD]** `dataset_venn_claude_code.png` - Gene overlap between our 648 ECM genes âˆ© external genes

---

## 6.0 Overall Validation Verdict

### 6.1 Summary of Success Criteria

| Test | Metric | Target | Achieved | Pass/Fail |
|------|--------|--------|----------|-----------|
| Datasets found | n | â‰¥ 2 | 6 | âœ… PASS |
| Gene overlap | % | â‰¥ 70% | TBD | â³ PENDING |
| H08 S100 model | RÂ² | â‰¥ 0.60 | TBD | â³ PENDING |
| H06 Biomarkers | AUC | â‰¥ 0.80 | TBD | â³ PENDING |
| H03 Velocities | Ï | > 0.70 | TBD | â³ PENDING |
| Meta-analysis | IÂ² | < 50% (â‰¥15/20) | TBD | â³ PENDING |

### 6.2 Validation Scenario

**[TO BE DETERMINED]**

**Scenario 1: Strong Validation (BEST CASE)**
- H08 RÂ² â‰¥ 0.65 â†’ S100 pathway CONFIRMED
- H06 AUC â‰¥ 0.85 â†’ Biomarkers validated for clinical use
- H03 Ï > 0.75 â†’ Tissue ranking universal
- IÂ² < 40% â†’ Aging signatures stable
- **Action:** Publish findings, proceed to clinical trials

**Scenario 2: Moderate Validation**
- Some targets met, others close
- Focus on STABLE proteins only
- Investigate context-dependence
- **Action:** Targeted follow-up studies

**Scenario 3: Poor Validation (FAILURE)**
- H08 RÂ² < 0.40 â†’ Overfitting confirmed
- H06 AUC < 0.70 â†’ Biomarkers fail
- IÂ² > 60% â†’ High heterogeneity
- **Action:** Re-evaluate all hypotheses, require external validation for ALL future work

### 6.3 Clinical Translation Implications

**If validation successful:**
- âœ… FDA submission benefits from multi-cohort validation
- âœ… Biomarker assay (F13B, S100A9) can cite independent replication
- âœ… S100â†’stiffness model deployable in clinical decision support

**If validation fails:**
- âš ï¸ Recognize limitations
- âš ï¸ Avoid premature clinical translation
- âš ï¸ Refocus on mechanistic understanding

---

## 7.0 Deliverables

### 7.1 Code & Scripts

**âœ… COMPLETED:**
- [x] `dataset_search_claude_code.py` - PRIDE/ProteomeXchange API queries
- [x] `data_harmonization_claude_code.py` - External data preprocessing
- [x] `transfer_learning_h08_claude_code.py` - S100 model validation
- [x] `meta_analysis_claude_code.py` - Combine old + new data, IÂ² calculation

**â³ PENDING:**
- [ ] `transfer_learning_h06_claude_code.py` - Biomarker panel validation
- [ ] `transfer_learning_h03_claude_code.py` - Velocity correlation

### 7.2 Data Tables

**âœ… COMPLETED:**
- [x] `external_datasets_summary_claude_code.csv` - Metadata for all found datasets
- [x] `discovered_datasets_claude_code.csv` - Detailed search results

**â³ PENDING (awaiting data download):**
- [ ] `h08_external_validation_claude_code.csv` - RÂ², MAE on external data
- [ ] `h06_external_validation_claude_code.csv` - AUC on external data
- [ ] `h03_velocity_comparison_claude_code.csv` - Our vs external velocities
- [ ] `meta_analysis_results_claude_code.csv` - Combined effect sizes, IÂ²
- [ ] `protein_stability_claude_code.csv` - Stable vs variable classification
- [ ] `gene_overlap_claude_code.csv` - Overlap % per dataset

### 7.3 Visualizations

**â³ PENDING:**
- [ ] `dataset_venn_claude_code.png` - Gene overlap
- [ ] `h08_transfer_scatter_claude_code.png` - Predicted vs actual stiffness
- [ ] `h06_roc_external_claude_code.png` - ROC curve
- [ ] `velocity_correlation_claude_code.png` - Our vs external velocities
- [ ] `meta_forest_plot_claude_code.png` - Forest plot (top 10 proteins)
- [ ] `heterogeneity_heatmap_claude_code.png` - IÂ² for all proteins Ã— tissues

### 7.4 External Datasets

**ğŸ“ Directory Structure:**
```
external_datasets/
â”œâ”€â”€ PXD011967/
â”‚   â”œâ”€â”€ raw/                 # Downloaded supplementary files
â”‚   â”œâ”€â”€ metadata.json        # Study information
â”‚   â””â”€â”€ PXD011967_processed_zscore.csv
â”œâ”€â”€ PXD015982/
â”‚   â”œâ”€â”€ raw/
â”‚   â”œâ”€â”€ metadata.json
â”‚   â””â”€â”€ PXD015982_processed_zscore.csv
â””â”€â”€ merged_external_zscore.csv  # Combined external data
```

---

## 8.0 Limitations and Future Work

### 8.1 Current Limitations

1. **Data access delays:** FTP download issues, supplementary file locations
2. **Tissue heterogeneity:** External datasets may have different tissues than training data
3. **Technical variation:** Different MS platforms (TMT, LFQ, QconCAT)
4. **Sample size:** External datasets smaller than our merged dataset
5. **Cell 2025 data:** Accession not yet located

### 8.2 Future Validation Strategies

1. **Prospective validation:** Collect NEW aging cohort specifically for validation
2. **Cross-species validation:** Test on mouse datasets
3. **Longitudinal validation:** Test on temporal trajectories (if data available)
4. **Plasma validation:** Extend to liquid biopsies (if ECM proteins detected)

### 8.3 Recommended Next Steps

**If Strong Validation:**
- Write manuscript for publication
- Develop clinical assay for biomarkers
- Apply for funding for clinical trials

**If Moderate Validation:**
- Focus on STABLE proteins only
- Investigate tissue-specific effects
- Collect larger validation cohort

**If Poor Validation:**
- Acknowledge overfitting in H01-H12 results
- Require external validation for ALL future hypotheses
- Re-analyze with more conservative statistics

---

## 9.0 Conclusion

**[FINAL CONCLUSION TO BE WRITTEN AFTER DATA ANALYSIS]**

**Current Status:** Data acquisition and harmonization phase

**Key Achievement:** Systematic identification of 6 independent datasets for validation

**Next Milestone:** Download and process PXD011967 and PXD015982 data

**Expected Timeline:**
- Data download: 1-2 days
- Data processing: 2-3 days
- Transfer learning validation: 1-2 days
- Meta-analysis: 1 day
- Final report: 1 day

**Critical Question:** Are Iterations 01-03 findings ROBUST or OVERFIT?

**Answer:** [TO BE DETERMINED]

---

## References

1. **PXD011967:** Ferri et al. (2019). "Discovery proteomics in aging human skeletal muscle." eLife. DOI: 10.7554/eLife.49874
2. **PXD015982:** Richter et al. (2021). "Alterations in ECM composition during aging and photoaging of the skin." Matrix Biol Plus. PMID: 33543036
3. **Cell 2025:** Ding et al. (2025). "Comprehensive human proteome profiles across a 50-year lifespan." Cell. PMID: 40713952
4. **H08 Results:** `/iterations/iteration_03/hypothesis_08_s100_calcium_signaling/`
5. **H06 Results:** `/iterations/iteration_02/hypothesis_06_biomarker_discovery_panel/`
6. **H03 Results:** `/iterations/iteration_01/hypothesis_03_tissue_specific_inflammation/`
7. **PRIDE Database:** https://www.ebi.ac.uk/pride/
8. **ProteomeXchange:** http://www.proteomexchange.org/
9. **MassIVE:** https://massive.ucsd.edu/
10. **Higgins et al. (2003):** "Measuring inconsistency in meta-analyses." BMJ. (IÂ² statistic reference)

---

**Document Version:** 1.0 - Data Acquisition Phase
**Last Updated:** 2025-10-21
**Author:** claude_code agent
**Status:** ğŸš§ IN PROGRESS - Awaiting external data download
